




RealRate

PHARMACEUTICAL 2025

Biofrontera Inc
Rank 160 of 225

us.com the alternative.com
PERFECT FOR AMERICAN COMPANIES AND WEBSITES TARGETING THE AMERICAN MARKET



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biofrontera Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Biofrontera Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 75% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	20,700
Cost of Goods Sold	0
Intangible Assets	35
Liabilities, Current	12,021
Liabilities, Non-Current	299
Other Assets	1,286
Other Compr. Net Income	0
Other Expenses	52,464
Other Liabilities	5,348
Other Net Income	-527
Other Revenues	37,321
Property and Equipment	80
Research and Development	2,089
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	22,101
Liabilities	17,668
Expenses	54,553
Revenues	37,321
Stockholders Equity	4,433
Net Income	-17,759
Comprehensive Net Income	-17,759
BaseVar	66,085
ECR before LimitedLiability	-41%
Economic Capital Ratio	139%